Loss-of-Function Mutations in SOX10 Cause Kallmann Syndrome with Deafness  by Pingault, Veronique et al.
ARTICLE
Loss-of-Function Mutations in SOX10
Cause Kallmann Syndrome with Deafness
Veronique Pingault,1,2,3,* Virginie Bodereau,3 Viviane Baral,1,2 Severine Marcos,4 Yuli Watanabe,1,2
Asma Chaoui,1,2 Corinne Fouveaut,5 Chrystel Leroy,5 Odile Ve´rier-Mine,6 Christine Francannet,7
Delphine Dupin-Deguine,8 Franc¸oise Archambeaud,9 Franc¸ois-Joseph Kurtz,10 Jacques Young,11
Je´roˆme Bertherat,12 Sandrine Marlin,13 Michel Goossens,1,2,3 Jean-Pierre Hardelin,14 Catherine Dode´,4,5
and Nadege Bondurand1,2
Transcription factor SOX10 plays a role in themaintenance of progenitor cellmultipotency, lineage specification, and cell differentiation
and is a major actor in the development of the neural crest. It has been implicated in Waardenburg syndrome (WS), a rare disorder
characterized by the association between pigmentation abnormalities and deafness, but SOX10 mutations cause a variable phenotype
that spreads over the initial limits of the syndrome definition. On the basis of recent findings of olfactory-bulb agenesis in WS indi-
viduals, we suspected SOX10 was also involved in Kallmann syndrome (KS). KS is defined by the association between anosmia and
hypogonadotropic hypogonadism due to incompletemigration of neuroendocrine gonadotropin-releasing hormone (GnRH) cells along
the olfactory, vomeronasal, and terminal nerves. Mutations in any of the nine genes identified to date account for only 30% of the KS
cases. KS can be either isolated or associated with a variety of other symptoms, including deafness. This study reports SOX10 loss-of-
function mutations in approximately one-third of KS individuals with deafness, indicating a substantial involvement in this clinical
condition. Study of SOX10-null mutant mice revealed a developmental role of SOX10 in a subpopulation of glial cells called olfactory
ensheathing cells. These mice indeed showed an almost complete absence of these cells along the olfactory nerve pathway, as well as
defasciculation and misrouting of the nerve fibers, impaired migration of GnRH cells, and disorganization of the olfactory nerve layer
of the olfactory bulbs.Introduction
SOX10 belongs to the SOX transcription-factor family,
whose members are involved in a multitude of develop-
mental and cellular processes.1 First identified as a glial
cell transcription factor, it was soon revealed as a major
player in the development of neural crest (NC) cells. NC
cells are a population of multipotent precursor cells that
emerge at the borders of the neural tube, migrate ex-
tensively throughout the embryo, and differentiate into
a variety of cell types, including skin pigment cells and
neurons and glia of the peripheral and enteric nervous
systems.2 SOX10 plays a role in the maintenance of pro-
genitor multipotency, specification, and differentiation
of numerous cell types through the regulation of several
transcriptional targets.1,3–5 Its involvement in Waarden-
burg syndrome (WS) contributed significantly to the
understanding of its function in NC cells in general and
in the melanocytic and enteric lineages in particular.6
WS is a clinically and genetically heterogeneous condi-
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The Amand abnormal pigmentation of the hair, skin, and iris. Four
subtypes (WS1–WS4 [MIM 193500, 193510, 148820,
277580, respectively]) and a neurological variant (periph-
eral demyelinating neuropathy, central dysmyelinating
leukodystrophy, Waardenburg syndrome, Hirschsprung
disease [PCWH (MIM 609136)]) have been described.6
Since 1998, approximately 100 heterozygous point muta-
tions or deletions of SOX10 (MIM 602229) have been
reported, first in WS4 (WS with Hirschsprung disease,
also called megacolon),7 then in its neurological variant,8
and finally in WS2 (WS without Hirschsprung disease)9
(see also the WS gene mutation database at LOVD [Leiden
Open Variation Database]).6
To delineate the range of temporal-bone abnormalities
associated with impaired SOX10 function, we recently per-
formed a study of MRI and/or computed–tomography (CT)
scans of inner ears from 15 WS individuals. Incidentally,
this study also revealed an unexpectedly high frequency
of olfactory-bulb agenesis (88% of the cases who could
be analyzed),10 a finding that had been described only
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Notably, one of the males included in our radiological
study had previously been reported as having anosmia
and hypogonadism.9
The association between anosmia and hypogonado-
tropic hypogonadism is known as Kallmann syndrome
(KS [MIM 147950, 244200, 308700, 610628, 612370, and
612702]) and is explained by a pathological sequence in
embryonic development. Premature interruption of the
vomeronasal and terminal nerve fibers in the peripheral
olfactory system have been shown to result in incomplete
migration of the neuroendocrine gonadotropin-releasing
hormone (GnRH) cells along these nerves and to thus
preclude them from penetrating into the forebrain and
reaching their final destination in the preoptic and
hypothalamic region.12 The prevalence of KS has been
estimated at 1 in 8,000 males and 1 in 40,000 females. To
date, nine genes—namely KAL1, FGFR1, FGF8, PROKR2,
PROK2, WDR11, HS6ST1, CHD7, and SEMA3A (MIM
300836, 136350, 600483, 607123, 607002, 606417,
604846, 608892, and 603961, respectively)—have been
implicated, but mutations in any of these genes have
been identified in only approximately 30% of KS individ-
uals.13 KS can be associated with a variety of nonolfactory,
nonreproductive symptoms, including deafness, but the
association between KS and deafness has so far received
little genetic explanation.
Here, we asked whether persons affected by KS carry
mutations in SOX10. We found a notable prevalence
(about 38%) of SOX10mutations in a group of individuals
presenting with the clinical association between KS and
hearing impairment, thereby shedding new light on this
clinical association. We showed that these mutations
affect SOX10 function in vitro. Homozygous Sox10mutant
mice show an almost complete absence of olfactory en-
sheathing cells (OECs) along the olfactory, vomeronasal,
and terminal nerves, abnormal fasciculation and axonal
misrouting of the olfactory neurons, impaired GnRH cell
migration, and disorganization of the olfactory-nerve
layer of the olfactory bulbs.Subjects and Methods
Subjects
This study was approved by the French national research-ethics
committee (Agence de Biomedicine, Paris, France). Seventeen
cases (nine males and eight females) presenting with KS and at
least oneWS-like feature were investigated, as well as 86 ‘‘random’’
cases (67 males and 19 females), 20 of whom had various nonol-
factory, nonreproductive associated anomalies (including eight
with cleft lip or palate), who were addressed for genetic explora-
tion of KS. Hypogonadism was diagnosed on the basis of clinical
and hormonal evaluation, whereas anosmia and hyposmia were
diagnosed on the basis of the individual’s interview and were
confirmed by olfactory tests with increasing concentrations of
odorant molecules (olfactometry) and/or MRI showing agenesis
of the olfactory bulbs. Informed consent for genetic testing was
obtained. Genomic DNA was extracted from peripheral-blood708 The American Journal of Human Genetics 92, 707–724, May 2, 2leukocytes according to standard protocols. These individuals
did not carry mutations in the coding sequences of previously
analyzed genes, specifically, KAL1, FGFR1, FGF8, PROKR2, and
PROK2, all involved in KS.Mutation Screening
The coding exons of SOX10 were analyzed by Sanger sequencing
of the PCR products as previously described.9 Mutations were
named according to the international nomenclature based on
RefSeq accession number NM_006941.3 for SOX10 cDNA.
SOX10 deletions or rearrangements were sought with the use of
quantitative multiplex fluorescent PCR with a method slightly
modified from that of Bondurand et al.9 The three coding exons
were amplified in five amplicons sorted in two different reaction
mixes. The sequences of the primers used are available upon
request. Individuals carrying a SOX10 mutation were further
tested for the presence of mutations in the other genes involved
in KS or in nonsyndromic congenital hypogonadotropic hypogo-
nadism; specifically, these genes were CHD7, WDR11, HS6ST1,
SEMA3A, GNRHR, GNRH1, TACR3, TAC3, KISS1R, and KISS1. To
confirm the de novo occurrence of the mutation, we conducted
a comparison with the parental DNA (when available) through
analysis of six microsatellites located on different chromosomes
by using the linkage mapping set (Applied Biosystems) according
to the manufacturer’s instructions.Animals and Genotyping
The generation and genotyping of Sox10lacZ mice (Sox10tm1Weg)
have been described previously.14 Experiments were performed
in accordance with the ethical guidelines of the Institut National
de la Sante´ et de la Recherche Me´dicale. Embryos at embryonic
day (E) 12.5 and E14.5 were obtained from staged pregnancies,
fixed in 4% paraformaldehyde (PFA) at 4C, and frozen in an
optimal-cutting-temperature compound. Head sections (16 mm
thick) were cut with a Leica CM3050S cryostat. Alternatively,
embryo heads were fixed in 1% PFA and 0.2% glutaraldehyde
and used for X-Gal staining.Immunostaining and X-Gal Staining
X-Gal staining followed standard procedures. Immunostaining
of mouse embryo sections was performed as described.15 The pri-
mary antibodies used were anti-SOX10 (N-20 or D-20) (goat, 1/50,
Santa Cruz), anti-TUJ1 (mouse, 1/1,000, Eurogentec), anti-BLBP/
BFABP (rabbit, 1/5,000, kindly provided by T. Mu¨ller),16 anti-P75
(rabbit, 1/500, Promega), anti-S100 (rabbit, 1/400, Dako Cytoma-
tion), anti-GnRH (rabbit, 1/500, Abcam), and anti-b-galactosidase
(chicken, 1/500, Abcam). Secondary antibodies were anti-goat-
FITC, anti-rabbit-Cy3, anti-mouse-Cy3, anti-goat-Alexa Fluor 555,
anti-rabbit-Alexa Fluor 488, anti-mouse-Alexa Fluor 647, anti-
guinea-pig-Cy3, and anti-chicken-Alexa Fluor 488 (1/200, Invitro-
gen or Jackson ImmunoResearch). TUNEL staining was performed
with the In Situ Cell Death Detection kit, fluorescein (Roche)
according to the manufacturer’s instructions. We estimated the
total number of GnRH cells by counting the GnRH-positive cell
bodies in more than two-thirds of the sections, from the vomero-
nasal organ to the end of their migration pathway. The number
of GnRH cells on the missing slides was scored as the mean of the
previous and following ones. Preparations weremounted in Vecta-
shield and examined with an Olympus SZH10 stereo-microscope
coupled to the Visilog capture program or a Zeiss Axioplan 2
confocal microscope coupled to theMetamorph software package.013
Human Tissues
A human fetus was obtained from a medically terminated
pregnancy at 8 weeks of embryonic development (the parents
provided written informed consent). After fixation in a 4%
formaldehyde solution, the head was embedded in paraffin. Serial
sagittal sections (4 mm thick) were cut with a Microm HM340E
microtome and collected on Superfrost Plus slides (Thermo Scien-
tific). Immunochemistry analysis was conducted as described17
with the SOX10, TUJ1, and S100 antibodies cited above. Because
of the limited number of slides, double SOX10/S100 staining
was performed on the nasal mesenchyme only.
Plasmids
The pECE-SOX10, pCMV-SOX10Myc, pECE-PAX3, pECE-EGR2,
pGL3-MITFdel1718, and pGL3-Cx32 vectors have been described
previously.18–20 Themutations identified were introduced into the
pECE-SOX10 (in the case of the c.2T>G mutation) or pCMV-
SOX10Myc constructs by site-directed mutagenesis with the use
of the QuikChange mutagenesis kit (Stratagene). The pGL3-MPZ
construct was kindly provided by J. Svaren.21
Cell Culture, Transfection, and Reporter Assays
HeLa cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum and transfected with
Lipofectamine Plus reagent (Invitrogen). Cells were plated on
12-well plates and transfected 1 day later with 0.175 mg of each
effector and reporter plasmid for the MITF (microphthalmia-
associated transcription factor) and GJB1 (also known as Cx32)
promoter study. In the MPZ enhancer study, 0.250 mg of reporter
plasmid was used. As far as the competition assays are concerned,
increasing amounts of altered SOX10 plasmids (0.175, 0.350, or
0.525 mg) were mixed with a fixed amount of wild-type SOX10
plasmid (0.175 mg) and reporter constructs. In each case, the total
amount of plasmid was kept constant by the addition of empty
pECE or pCMV-Myc vectors. Twenty-four or 48 hr after transfec-
tion, cells were washed twice with PBS and lysed, and the extracts
were assayed for luciferase activity with the Luciferase Assay
System (Promega) as described previously.9,19,22 Production of
SOX10 was assessed by immunoblot analysis according to stan-
dard protocols.23 Quantification was performed with GeneTools
v.3.05 software. Alternatively, cultures were fixed in 4% PFA for
10 min at room temperature, and immunocytochemistry was
performed as described above with the use of anti-SOX10 (N-20
or D-20).
In Silico Analysis of the Mutations
Mutations were analyzed with PolyPhen-2, SIFT, Alamut 2.0.2
software for splicing, dbSNP, the 1000 Genomes Project, and the
National Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project Exome Variant Server. The conformation
files for DNA-bound SOX17 were imported from the Protein
Data Bank (accession number 3F27) and visualized with Swiss-
PdbViewer software.24,25Results
SOX10 Mutations Are Frequent in Individuals
with KS and Deafness
We first searched for SOX10 point mutations and deletions
in individuals who had been diagnosed with KS and whoThe Amalso presented with one or several of the known features
of SOX10-linked WS. We screened 17 cases (9 males and
8 females) previously found negative for mutations in
the main genes involved in KS; 13 of them presented
with deafness (unilateral in three cases), two had pigmen-
tation defects (hair and skin hypopigmentation; early
graying in one, who was deaf), two had intellectual
disability, and one showed psychomotor delay (both of
these latter two features can be found in the neurological
variant of WS [PCWH]). Eleven cases also had additional
symptoms unrelated to WS.
Six new SOX10 nucleotide changes were identified in
this cohort: a mutation of the initiation codon (c.2T>G
[p.?]), two nucleotide changes predicted to cause missense
substitutions within the HMG domain (c.331T>G
[p.Phe111Val] and c.424T>C [p.Trp142Arg]), a splice-site
mutation (c.698-1G>C), a 1 bp deletion predicted to result
in a frameshift (c.1290del [p.Ser431Argfs*71]), and finally
a nucleotide change predicted to result in a missense
substitution located in the transactivation domain
(c.1298G>A [p.Arg433Gln]). These changes were not
found in at least 50 control individuals (100 chromo-
somes) of the same origin, and the relevant databases
(dbSNP, 1000 Genomes Project, NHLBI Exome Variant
Server) did not provide evidence that any of these varia-
tions are found in control populations.
Clinical and molecular findings in persons carrying
SOX10 mutations are summarized in Table 1 (cases A–F).
All six individuals had anosmia and either absent or
delayed spontaneous puberty. Two males had cryptorchi-
dism, and one also had a micropenis. One of them demon-
strated early graying of the hair. Interestingly, all but one
were deaf. Pedigrees of the two familial cases are repre-
sented in Figure S1A, available online. A sample from the
clinically affected mother of case D (with anosmia and
deafness) (see Table 1 and Figure S1A) was obtained, and
cosegregation of the mutation and the disease was
confirmed. Parents could also be analyzed for two of the
sporadic cases (cases B and E), and the mutation was
proved to be de novo in both cases.
Five Mutations Result in Impaired SOX10 Function
In silico prediction suggested likely pathogenic conse-
quences of all six mutations. Several programs predicted
the splice-site mutation, c.698-1G>C, to result in complete
loss of the last splice acceptor site and to have conse-
quences similar to those of previously identified splice-
site mutations at the same location (c.698-2A>C and
c.698-2A>T).26,27 PolyPhen-2 and SIFT predicted the three
missense mutations to be ‘‘likely damaging’’ and ‘‘not
tolerated,’’ respectively. Functional effects of themutations
were tested through in vitro analysis.
The p.Phe111Val, p.Trp142Arg, p.Ser431Argfs*71, and
p.Arg433Gln alterations were tested with a construction
allowing production of SOX10 with a Myc tag at its amino
terminus. After confirmation of the protein production
by immunoblot analysis (Figure 1A), we first comparederican Journal of Human Genetics 92, 707–724, May 2, 2013 709
Table 1. Phenotypes of the KS Individuals Carrying SOX10 Mutations
Case
Age
(Years) Gender Occurrence
FSH (UI/l)
Basal Peak
LH (UI/l)
Basal Peak
E2
(pg/ml)
T
(ng/ml)
Sponta
-neous
Puberty
Sense of
Smell
Olfactory
Bulb (MRI) Hearing
Other Clinical
Signs
DNA
Mutation
Protein
Alteration
In Silico
Evidence
In Vitro
Evidence
Clinically Selected KS Individuals
A 26 M familial 0.2–2.0 0.4–2.1 - <1.7 no anosmia agenesis unilateral
deafness
micropenis,
cryptorchidism,
white hair
(22 years old)
c.2T>G p.? pathogenic pathogenic
B 18 F sporadic 2.8–ND 0.3–ND <10 - no anosmia agenesis prelingual
deafness
ptosis c.331T>G
(de novo)
p.Phe111Val pathogenic pathogenic
C 39 F sporadic <0.5–ND 0.87–ND 42 - no anosmia ND prelingual
deafness
obesity
(BMI ¼ 51)
c.424T>C p.Trp142Arg pathogenic pathogenic
D 25 F familial
(anosmia
and deafness
in mother)
2.1–7.9 0.8–8.0 20 - delayed anosmia agenesis prelingual
deafness
- c.698-1G>C p.spl? pathogenic -
E 20 M sporadic NA NA - NA delayed anosmia ND prelingual
deafness
cryptorchidism,
SEMA3A
c.1303G>A
(p.Val435Ile)
(þ/)
c.1290del
(de novo)
p.Ser431Argfs*71 pathogenic pathogenic
F 20 M sporadic NA NA - NA - anosmia ND normal intellecual
disability,
dysmorphy,
polymalformation
c.1298G>A p.Arg433Gln pathogenic not
pathogenic
Random KS Individuals
G 33 M familial?
(a brother is
most likely
anosmic)
0.8–0.9 0.41–0.6 - 0.23 no anosmia ND hypoacusis ptosis c.323T>C p.Met108Thr pathogenic pathogenic
H 19 F sporadic <1.0–4.4 0.5–8.0 <0.1 - no anosmia agenesis normal macroscelia c.451C>T p.Arg151Cys pathogenic pathogenic
The age indicated was at the time of DNA sampling, usually age of diagnosis. Normal ranges are as follows: FSH/LH, 2–20 UI/l; E2,>20 pg/ml; and T, 2–10 ng/ml. The following abbreviations are used: M,male; F, female; BMI,
body mass index; E2, estradiol; T, testosterone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; ND, not determined; and NA, not available.
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Figure 1. Functional Analysis of the Altered SOX10 Proteins
(A) Immunoblott analysis showing wild-type (WT) or altered SOX10 proteins with the use of an antibody directed against the carboxy
terminal portion of the protein.
(B and C) Luciferase reporter-gene analysis. HeLa cells were cotransfected with the wild-type (WT) or altered SOX10 expression vector
and a reporter construct containing theMITF promoter (B) orMPZ intronic enhancer (C) and known SOX10 cofactor expression vectors,
i.e., PAX3 (B) or EGR2 (C). Reporter-gene activation is presented as luciferase fold induction relative to the empty vector. Results are the
mean5 SEM of at least three different experiments, each performed in duplicate.
(D) Detection and localization of the c.2T>G (p.?) altered protein. HeLa cells were transfected with wild-type (left panels) or altered
c.2T>G (p.?) (right panels) SOX10 constructs. Nuclei were counterstained with TO-PRO-3 iodide (blue). Transfected cells were immuno-
stained with anti-SOX10 (red) directed against either the amino terminus (N20) or the carboxy terminus (D20) of the protein, as indi-
cated. The merged images are presented below. A higher magnification of SOX10 labeling is also shown in gray (bottom panels).
(E) Luciferase reporter-gene analysis. HeLa cells were cotransfectedwith thewild-type (WT) or altered c.2T>G (p.?) SOX10 expression vec-
tors and a reporter construct containing theMITF promoter (left panel), theMPZ intronic enhancer (central panel), or theGJB1 promoter
(right panel) and the PAX3 (left panel) or EGR2 (central and right panels) expression vector. Reporter-gene activation is presented as fold
induction relative to the empty vector. Results are the mean5 SEM of at least three different experiments, each performed in duplicate.
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Figure 2. Subcellular Localization of the Altered SOX10 Proteins and Summary of All SOX10 Alterations Found in This Study
(A) Three-dimensional representation showing the location within the HMG-domain residues affected by the identified missense sub-
stitutions and a three-dimensional view of the SOX17 HMG domain (backbone in red) that forms three a helices (white ribbons) bound
to its DNA target (blue). Upper panel: the four residues that form the hydrophobic core are shown in yellow. Lower panel: the residues
corresponding to SOX10 Phe111 and Trp142, both belonging to the hydrophobic core, are indicated in green and pink, respectively.
(B) Subcellular localization of wild-type and altered proteins by immunostaining. HeLa cells transfected with wild-type (left panels)
or altered (other panels) SOX10 constructs. Nuclei were counterstained with TO-PRO-3 iodide (blue). Transfected cells were immu-
nostained with anti-SOX10 (red). Images shown are with D20, but similar results were obtained with N20 directed against the amino
terminus of the protein. The merged images are presented below. A higher magnification of SOX10 labeling is also shown in gray
(bottom panels).
(legend continued on next page)
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the transactivation capacities of the altered proteins on the
MITF promoter and MPZ (myelin protein zero; P0)
enhancer reporter constructs either alone or in synergy
with known SOX10 partner transcription factors, PAX3
(paired box 3) and EGR2 (early growth response 2), res-
pectively (Figures 1B and 1C).19,21 The p.Phe111Val,
p.Trp142Arg, and p.Ser431Argfs*71 altered SOX10 were
unable to transactivate the MITF reporter construct
alone or in synergy with PAX3, whereas the p.Arg433Gln
altered SOX10 behaved like the wild-type protein. On
the MPZ enhancer reporter construct, the p.Phe111Val,
p.Trp142Arg, and p.Ser431Argfs*71 altered SOX10 also
lost their transactivation capacities alone and demon-
strated variable synergistic activity with EGR2 (specifically,
it was conserved for p.Phe111Val and p.Trp142Arg but
lost for p.Ser431Argfs*71). Again, the p.Arg433Gln altered
protein showed no change when compared with wild-type
SOX10. Together, these findings indicated loss of function
of the first three alterations and no pathogenic effect of
the p.Arg433Gln substitution in vitro. These findings are
consistent with the observation that Arg433 is located
in the transactivation domain, where no WS-causing
missense substitutions have been characterized thus far,
whereas Phe111 and Trp142 are located within the highly
conserved HMG domain, as are the amino acid residues
modified by the previously identified SOX10 missense
substitutions.24
Because of its location in the translation initiation
codon, the c.2T>G mutation was tested with a SOX10
construction allowing production of an untagged protein.
Although not detected in immunoblot analysis performed
under standard conditions (data not shown), the altered
protein was visualized by immunocytochemistry. Use of
an antibody directed against the carboxy-terminal portion
of SOX10 revealed that an altered protein was produced
and localized within the nucleus, as was the wild-type
protein (Figure 1D, D20-Ab). Notably, we failed to detect
the altered protein with another antibody directed against
the amino terminus of SOX10 (Figure 1D, N20-Ab), which
supports the use of a downstream methionine as an
alternative initiation codon. This altered protein showed
either absent or reduced transactivation capacity on the
MITF,MPZ, or GJB1 (another SOX10 target gene, encoding
connexin 32) reporter constructs (Figure 1E). Synergistic
activity was lost with PAX3, whereas it was retained with
EGR2 on MPZ, but not on GJB1 (Figure 1E).
The six mutations were also tested in a competition
assay on the MITF promoter. They did not show any
dominant-negative effect at a ratio of 1:1 and 2:1 to the
wild-type protein (Figure S1B). Only at a ratio of 3:1 did(C) Three-dimensional representation of the location of the HMG-do
‘‘random’’ KS individuals, as in (A). Upper panel: the residue correspon
in green. Lower panel: the residue corresponding to Met108, in con
(D) Subcellular localization of the p.Arg151Cys and p.Met108Thr alt
(E) Schematic representation of the SOX10 protein and the alteration
domain; K2, K2 domain; HMG, HMG domain; and TA, transactivati
The Amthe alterations (except p.Arg433Gln) induce a decrease of
the luciferase induction.
Functional analysis of SOX10 missense mutations
previously identified in the context of WS allowed us
to show that amino acid substitutions in close contact
with the main hydrophobic core of the HMG domain
alter subcellular localization of the protein and thus lead
to its accumulation in nuclear foci.24 The hydrophobic
core is composed of four highly conserved residues,
two tryptophans, and two phenylalanines, which are
located at the intersection of the three a helices that
compose the HMG domain and maintain their structural
shape. The p.Phe111Val and p.Trp142Arg substitutions
described here both remove one of the hydrophobic
core components (Figure 2A). We therefore analyzed
the effects of these substitutions on the subcellular locali-
zation of SOX10 by immunocytochemistry. Whereas
the p.Ser431Argfs*71 and p.Arg433Gln altered proteins
showed a nuclear localization pattern similar to that
observed for the wild-type protein (Figure 2B), the
p.Phe111Val and p.Trp142Arg altered proteins showed
partial cytoplasmic relocalization (consistent with the
location of Phe111 and Trp142 within the bipartite nuclear
localization signals [NLSs] and the nuclear export signal
[NES], respectively) and subnuclear accumulation in foci.
Together, these results strongly indicate that five of
the six identified mutations have a pathogenic effect and
that all are found in individuals presenting with the
clinical association between KS and deafness.
SOX10 Mutations Are Rare in KS Individuals
without Hearing Impairment
We then aimed to determine whether SOX10 is also
involved in other clinical forms of KS, particularly in KS
without deafness. We screened 86 random KS individuals,
including 66 KS cases without associated features and
20 cases with nonolfactory, nonreproductive additional
symptoms, for SOX10 point mutations or deletions.
We identified two additional mutations (c.323T>C
[p.Met108Thr] and c.451C>T [p.Arg151Cys]) (Table 1,
cases G and H; see Figure S1C for case G pedigree) affecting
amino acid residues of the HMG domain. Notably, the
individual who carried the p.Met108Thr substitution
showed hypoacusis, whereas the absence of hearing
impairment was confirmed in the individual carrying the
p.Arg151Cys substitution.
Arg151 is located close to the hydrophobic core of
the protein (Figure 2C, upper panel), whereas the Met108
residue contacts both the hydrophobic core and the
DNA target (Figure 2C, lower panel) and is located in themain residues affected by the missense substitutions identified in
ding to Arg151, in contact with the hydrophobic core, is indicated
tact with the DNA target, is indicated in green.
ered proteins by immunostaining, as in (B).
s found in this study. Abbreviations are as follows: D, dimerization
on domain.
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bipartite NLS of SOX10. Its substitution could thus affect
the structure, DNA binding, and/or nuclear localization
of SOX10 as the primary defect. We performed immuno-
cytochemistry experiments to analyze the subcellular
location of the altered proteins. Both p.Met108Thr and
p.Arg151Cys missense substitutions resulted in partial
cytoplasmic relocalization of SOX10 and subnuclear
accumulation in foci (Figure 2D). Luciferase assays
confirmed the loss-of-function effect of these substitu-
tions on the MITF promoter both alone and in the pres-
ence of the cofactor PAX3 (Figure S1D).
The seven likely pathogenic alterations found in this
study are shown along with the main functional domains
of SOX10 (Figure 2E). Additional screening for mutations
in the genes involved in KS or congenital nonsyndromic
forms of hypogonadotropic hypogonadism was per-
formed in the individuals with a SOX10 mutation (A–H,
Table 1) and only yielded a SEMA3A heterozygous
missense variant (c.1303G>A [p.Val435Ile]) in case E.
This variant has been found at similar frequencies in KS
individuals and control subjects, although it has been
reported to have some deleterious functional conse-
quences in vitro.28
These results indicate that SOX10 mutations are rare in
KS individuals without associated features and confirm
that the clinical association between KS and hearing
impairment is more specific. We then used a mouse model
to explore the embryonic defect leading to KS as a result of
impaired SOX10 function.
SOX10 Is Expressed in Embryonic OECs in Mice
and Humans
OECs, peculiar glial cells involved in the growth and
guidance of the olfactory axons, have recently been
shown to derive from NC cells in mice and chicks.
SOX10 was used as a marker of NC-derived cells in these
studies, and its pattern of expression indeed suggested
that it is expressed by OECs.29–31 Given that OECs are
heterogeneous in the pattern of markers they express,32
we fully characterized the SOX10 expression profile
during development of the olfactory structures by using
antibodies directed against SOX10 and several markers
of OECs.
In the E12.5 mouse embryo, the olfactory, vomeronasal,
and terminal nerve fibers can be seen in the mesenchyme
surrounding the olfactory epithelium and converge on the
migratory mass, a heterogeneous group of cells located in
the frontonasal mesenchyme beneath the presumptive
olfactory bulbs. OECs are detected all along the nerve
pathway, where their cytoplasms ensheathe the axon bun-
dles, and begin to invade the olfactory nerve layer (ONL)
of the developing olfactory bulb at this stage (Figure 3A).
Immunostaining on coronal sections of the E12.5 embryo
head (Figure 3A) revealed that SOX10 is coexpressed with
the OEC marker BLBP (also known as BFABP), whereas it
showed mutually exclusive expression with the neuronal
marker TUJ1 (b3-tubulin). More specifically, SOX10714 The American Journal of Human Genetics 92, 707–724, May 2, 2(nuclear staining, red) and BLBP were coexpressed along
the olfactory, vomeronasal, and terminal nerve pathways,
in the frontonasal mesenchyme, and in the migratory
mass below the presumptive olfactory bulb (Figure 3B
and data not shown). SOX10-positive cells also expressed
the OEC markers P75 (also known as NGFR; note that
this marker is not specific to OECs and also labels most
cells in the nasal mesenchyme) and S100 along the
nerve fibers and in the nasal mesenchyme (Figure 3B).
By contrast, they did not express P75 and showed vari-
able S100 immunostaining within the migratory mass
(Figure 3B).
At E14.5, the olfactory epithelium developed. SOX10
demonstrated the same pattern of expression in OECs
(defined as BLBPþ, P75þ, S100þ, TUJ1 cells) of the nasal
mesenchyme and along the nerve pathway (Figure 3C
and data not shown). At this stage, the olfactory
bulb had formed from the rostral telencephalon, and
a continuous outer layer of SOX10-expressing cells,
corresponding to the ONL, was observed (Figure 3D).
These cells were positive for BLBP and negative for P75,
whereas only the outermost cells were positive for S100
(Figures 3D and 3E). Apart from observing OECs, we
observed some SOX10 expression in the nasal glands
(Figures S2A and S2B). We also confirmed the presence
of a few nonneuronal SOX10-expressing cells in the olfac-
tory epithelium at this stage (Figure S2C), as previously
reported.29,31
Finally, we studied SOX10 expression in the peripheral
olfactory system of a human embryo at 8 weeks of
embryonic development (this stage is equivalent to
mouse E14.5). Immunostaining experiments revealed
that SOX10-expressing cells (nuclear, green) were located
along the olfactory, vomeronasal, and terminal nerve
trajectories (TUJ1 staining, red) in the nasal mesenchyme
(Figure 4A), in the migratory mass, and in the olfactory
bulb (Figure 4B). Double staining of SOX10 with the
OEC marker S100 along the olfactory nerves confirmed
that SOX10-expressing cells are OECs (Figure 4C).
Together, these results confirm SOX10 expression in
OECs during early development of the peripheral olfactory
system in mice and humans.
The Sox10 Mutant Mouse Has OEC Defects
We then used mice bearing a Sox10 mutation (Sox10lacZ)14
to explore the embryonic defect leading to KS as a result
of impaired SOX10 function. We first performed X-Gal
staining to detect b-galactosidase (lacZ expression) in
heterozygous and homozygous mutant E14.5 embryos.
The olfactory bulbs had formed in both genotypes,
but an abnormal colonization of the olfactory bulbs
by X-Gal-stained (blue) OECs was apparent in homozy-
gotes (Figure 5A). We then compared b-galactosidase
expression with various markers by immunohisto-
chemistry on coronal sections. A general overview of the
olfactory system showed that the olfactory, vomeronasal,
and terminal nerves had formed in the homozygous013
Figure 3. SOX10 Expression in the Mouse Embryonic Olfactory System
(A) Double immunolabeling of the E12.5 embryo head (coronal sections) for SOX10 (red), the neuronal marker (TUJ1; blue), or the OEC
marker (BLBP; green). The boxed regions are the migratory mass and the nasal mesenchyme magnified in (B).
(B) Higher magnification of the vomeronasal nerve (left panel), nasal mesenchyme (middle panel), and migratory mass (right panel).
Triple labeling for SOX10 (red), the neuronal marker (TUJ1; blue), and an OECmarker (BLBP, P75, or S100 as indicated; green) is shown.
The dotted lines represent the limit between the olfactory epithelium and the mesenchyme.
(C) Double labeling of the E14.5 embryo olfactory epithelium andmesenchyme (coronal sections) for SOX10 (red), the neuronal marker
(TUJ1; blue), or the OEC marker (BLBP; green).
(D) Triple labeling of E14.5 embryo olfactory bulbs (coronal sections) for SOX10 (red), the neuronal marker (TUJ1; blue), or the OEC
marker (BLBP or P75 as indicated; green). The boxed regions in the medial ONL are magnified in (E).
(E) Higher magnification at the level of the medial ONL. Triple labeling for SOX10 (red), the neuronal marker (TUJ1; blue), and an OEC
marker (BLBP, P75, or S100 as indicated; green) is shown.
Abbreviations are as follows: M, mesenchyme; MM, migratory mass; OB, olfactory bulb; OE, olfactory epithelium; and VNO, vomero-
nasal organ.mutant embryos, but OECs (b-galactosidase-positive
cells) were almost absent in the nasal mesenchyme and
along the nerve pathway (Figure 5B and higher magni-The Amfication in Figure 5C). Only a few OECs were observed
in the upper part of the frontonasal mesenchyme,
under the migratory mass. By contrast, numerous OECserican Journal of Human Genetics 92, 707–724, May 2, 2013 715
Figure 4. SOX10 Expression in the
Human Embryonic Olfactory System
(A and B) Immunostaining of the head of
a human fetus at 8 weeks of embryonic
development (sagittal sections) at the level
of the nasal mesenchyme (A) or migratory
mass and olfactory bulb (B). Double label-
ing for SOX10 (green) and the neuronal
marker (TUJ1; blue) and counterstaining
with DAPI (blue) are shown. Abbreviations
are as follows: M, mesenchyme; MM,
migratory mass; OB, olfactory bulb; and
OE, olfactory epithelium.
(C) Immunostaining showing an olfactory
nerve at higher magnification. Double
staining for SOX10 (green) and the OEC
marker (S100; red) and counterstaining
with DAPI are shown.were present in the migratory mass and the ONL, but
they appeared to encircle the olfactory bulbs incompletely
by forming a thinner, disorganized, and discontinued
layer.
We then determined the expression pattern of OEC
markers in the absence of SOX10. In the upper part of
the frontonasal mesenchyme, the marker profile of the
few b-galactosidase-positive cells present in the mutant
homozygotes differed from that of cells in heterozygotes:
homozygotes had fainter BLBP and absent S100 labeling
in most of these cells, whereas P75 staining was pre-
served (Figure 5D). In the ONL of the olfactory bulbs,
BLBP staining was preserved, and S100 staining (normally
found in the outermost cell layer of the ONL) was lost,
but most, if not all, OECs were now positive for P75
(Figure 5E).
In summary, these results indicate an almost complete
absence of OECs in the nasal mesenchyme of the Sox10
homozygous mutant embryos, defective colonization of
the olfactory bulbs, and abnormal profiles of the remain-
ing OECs in both the nasal mesenchyme and the ONL of
the olfactory bulbs.
To explain these defects, we compared the development
of OECs in heterozygous and homozygous Sox10 mutant
embryos at an earlier stage. At E12.5, the absence of
OECs in most of the nasal mesenchyme was already visible
in the mutant homozygotes (Figure S3A). The migratory
mass had formed; however, defective colonization of the
olfactory-bulb anlage by OECs was already detectable on
more rostral sections (Figure S3B). To determine whether
the absence of OECs in the nasal mesenchyme was due
to apoptosis of Sox10-defective cells, we counted the
number of TUNEL-positive cells in the nasal mesenchyme.
We did not find a significant difference in the number of
apoptotic cells between heterozygous and homozygous
Sox10lacZ embryos (Figure S3C), indicating that the defect
responsible for the low number of OECs in the homozy-
gous mutant embryos occurred earlier or by a nonapop-
totic mechanism.716 The American Journal of Human Genetics 92, 707–724, May 2, 2The OEC Defect Impacts the Development
of Olfactory, Vomeronasal, and Terminal Nerves
and the Migration of Neuroendocrine GnRH Cells
OECs ensheathe the olfactory, vomeronasal, and terminal
nerve fibers and also contribute to axonal pathfinding,
fasciculation, and defasciculation.32 We thus looked at
the trajectory of these nerve fibers in the Sox10 mutant
embryos. TUJ1 staining on E14.5 heads showed that the
nerves had formed in mutant homozygotes despite the
almost complete absence ofOECs in thenasalmesenchyme
(Figure 6A). However, axons were abnormally routed; some
of them did not target the olfactory bulb and instead
contacted axons from the other side, dorsally to the nasal
septum (red arrowhead in Figure 6A). Furthermore, as a
result of the absence of OECs, axons were not ensheathed
along their most ventral trajectory, and their defascicula-
tion could be observed near the nasal septum (red arrow
in Figure 6A; defasciculation is also visible in Figure 5D).
Hypogonadism in KS results from the so-called olfacto-
genital fetopathological sequence, whereby incomplete
embryonic migration of the neuroendocrine GnRH cells
from the nose to the brain arises from the disruption of
vomeronasal and terminal nerve fibers.12 We therefore
analyzed the migration of these cells in the Sox10 mutant
embryo. In E14.5 wild-type and heterozygous embryos,
most GnRH cells had already left the extracerebral nerve
pathway and were migrating within the two cerebral hemi-
spheres. In homozygousmutant embryos, GnRH cells were
found to accumulate on the vomeronasal and terminal
nerve trajectories in the nasal mesenchyme (Figure 6B
and data not shown). GnRH cell count along the nerve
pathway confirmed this observation in that there was a
significantly larger number of GnRH cell bodies present
in the Sox10laZ homozygotes than in wild-type and hetero-
zygous embryos (Figure 6C). Although some GnRH cells
did reach the migratory mass in the homozygous mutant
embryos, few cells had penetrated into the forebrain en
route to the hypothalamic region (Figure 6D). The overall
number of GnRH cells appeared unchanged (estimated013
at 969 in wild-type, 949 in heterozygous mutant, and 937
in homozygous mutant embryos).
These results show that the Sox10 homozygous mutant
mice, which have a complete lack of SOX10, also undergo
an embryonic pathological sequence similar to that
responsible for KS. The defects we observed in the Sox10
homozygous mutant mice are schematized in Figure 7.Discussion
KS is genetically heterogeneous and has various modes of
transmission: it can be autosomal recessive, autosomal
dominant with incomplete penetrance, linked to the X
chromosome, or oligogenic. However, only 30% of cases
have mutations in any of the nine genes identified thus
far.13,28 Deafness is one of various nonolfactory, nonre-
productive anomalies that are sometimes found together
with KS.13 Its prevalence in KS individuals has been
estimated at approximately 5%.33 As our understanding
of the molecular basis of KS has progressed, deafness has
been reported in individuals with KAL1, FGFR1, FGF8,
or CHD7 mutations, but these cases remain relatively
rare.34–38 Given the high prevalence of hearing impair-
ment in the general population, the association between
KS and deafness might sometimes be coincidental, as was
shown in a family in which deafness cosegregated neither
with KS nor with the FGF8 mutation.39 Comparatively,
the remarkably large penetrance of deafness in the KS
individuals who carry mutations in SOX10 appears highly
significant.
We characterized seven different SOX10 mutations in
persons affected by KS. As in WS, the mutations were
found in the heterozygous state together with a dominant
mode of inheritance. Some phenotypic variation was
observed. In family D, the mother, who also carries the
mutation, suffered from deafness and anosmia but had
normal puberty and a spontaneous pregnancy. Although
mosaicism cannot be excluded, this finding most likely
refers to the usual phenotypic variability that is frequently
observed in developmental disorders, and particularly in
KS or SOX10-linked WS. Stochastic events and modifier
genes are often proposed to explain at least part of the
phenotypic variability. In this respect, the SEMA3A
sequence variant that was found in case E might influence
the expression of the disease.
In the first part of our study, five mutations were
found among 13 individuals with the clinical association
between KS and deafness, corresponding to a SOX10
involvement of 38%. This rate might be slightly overesti-
mated because a few KS individuals with deafness and
already known mutations in other genes had been
excluded. However, to date, SOX10 stands as the main
gene involved in this specific clinical association.
The hearing loss was sensorineural, profound, or total in
most cases. The audiograms of cases D and E are shown in
Figure S4 and illustrate a total loss of hearing in the twoThe Amears at all frequencies. In contrast, case G showed a mild
sensorineural hearing loss (30 dB at 1,000 and 2,000 Hz
in the left ear and 40 dB from 250 to 1,000 Hz in the right
ear). A striking finding is the high proportion of females
among persons carrying SOX10 mutations in this series
(four females and three males) given that KS has been
estimated to be three to five times more frequent in males
than in females.13 However, an approximately 1:1 sex ratio
was also found in the group of individuals with KS and
deafness (7 females out of 13 cases), an observation that
needs to be confirmed by further studies.
Seven of the eight SOX10 sequence variations identified
(four missense mutations, one frameshift, one splice-site
mutation, and one mutation of the initiation codon)
either result in or are predicted to result in an altered
production or function of SOX10 (Figure 2E). We per-
formed transactivation assays on two target genes of
SOX10, namely MITF and MPZ.19,21 MITF was chosen
because of its critical role in melanocyte development,
whereas MPZ was selected on the basis of its known ex-
pression in OECs.40 Our results do not support a delete-
rious effect of the p.Arg433Gln substitution. The other
seven alterations were found to alter subcellular locali-
zation and/or transactivation capacities, thus validating
their deleterious effect. The four missense substitutions
located in the HMG domain showed a peculiar aspect of
relocalization to nuclear bodies, which we had previously
observed for amino acid substitutions in close contact
with the main hydrophobic core of the HMG domain.24
Whether these foci are a cause or a consequence of the
pathogenic effect is still unclear.
The c.2C>T mutation affects the SOX10 initiation
codon. However, immunostaining of cells transfected
with cDNA carrying the mutation, with the use of anti-
bodies directed against the SOX10 amino or carboxy
terminus, showed that an in-frame protein is produced.
The first in-frame ATG codon corresponds to Met90 and,
if used, would produce a protein conserving the HMG
and transactivation domains but lacking most of the
dimerization domain.41 Because Met90 is the only in-
frame methionine more proximal to the two NLSs, this
hypothesis is consistent with our observation that the
protein produced did not relocalize to the cytoplasm.42
Significantly, one of the KS individuals had early graying
and deafness and therefore fulfilled the diagnosis criteria
for type 2 WS, but no pigmentation defects were reported
for the other cases. For some persons, clinical reevaluation
was possible after the identification of the SOX10 muta-
tion. The absence of WS-like pigmentation disturbance
was confirmed in case D and her mother, as well as in cases
B and C, whereas case E had belatedly developed a frontal
white forelock at approximately 25 years of age. No evi-
dence at this point indicates what makes a given SOX10
mutation a KS- or WS-causing mutation. As a whole, the
mutations we identified here were not typically different
from the mutations previously identified in WS except
for their relative frequency: we found mostly missenseerican Journal of Human Genetics 92, 707–724, May 2, 2013 717
Figure 5. OEC Defect in the E14.5 Sox10 Mutant Mice
(A) Whole-mount X-Gal staining of the head (facial view) in heterozygous (Sox10lacZ/þ, left panel) and homozygous (Sox10lacZ/lacZ, right
panels) mutant embryos. The skin was removed for visualization of the olfactory bulbs, indicated by the black arrowheads.
(B) General overview of the olfactory system upon triple labeling for b-galactosidase (green), the neuronal marker (TUJ1; blue), and the
OEC marker (BLBP; red), in Sox10 heterozygous (left panel) and homozygous (right panels) mutant embryos.
(legend continued on next page)
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Figure 6. Abnormal Nerve Fasciculation,
Axonal Pathfinding, and GnRH Cell
Migration in Sox10 Mutant Mice
(A) TUJ1 (upper panel) and b-galactosidase
(middle panel) immunostaining and a
merged image (lower panel) over the
nasal septum at a similar level of hetero-
zygous (Sox10lacZ/þ) and homozygous
(Sox10lacZ/lacZ) mutant E14.5 embryos, as
indicated. The arrow and arrowhead in
the homozygote indicate the defascicula-
tion of sensory axons and their misrouting
over the nasal septum, respectively.
(B) GnRH cells along the vomeronasal
nerve trajectory in wild-type (left panel)
and homozygous Sox10 mutant (right
panel) E14.5 embryos. TheGnRHimmuno-
staining is in red, DAPI staining is in blue,
and b-galactosidase immunostaining is in
green. Insets show higher magnifications.
(C) Box plots showing quantification of
the number of GnRH cells along the trajec-
tory of the vomeronasal nerve in wild-
type, heterozygous, and homozygous
mutant mouse embryos. Each dot corre-
sponds to the number of GnRH-positive
cell bodies counted on one side of a sec-
tion. The top and bottom of each box
represent the 25th and 75th percentiles,
respectively. The middle line is the me-
dian. Statistical significance was tested
with a Student’s t test. ***p < 0.0001.
The following abbreviation is used: ns,
not significant.
(D) DAPI (upper panel) and GnRH (lower
panel) staining of sections at the level of
the preoptic area in the wild-type (left),
heterozygous (center) and homozygous
(right) E14.5 embryos.
Abbreviations are as follows: OB, olfactory
bulb; OE, olfactory epithelium; NS, nasal
septum; and VNO, vomeronasal organ.mutations causing protein changes in the HMG domain
and a few protein-truncating mutations in our group of
KS individuals (most SOX10 mutations are predicted to
result in a truncated protein in WS), a finding that must
be confirmed in additional studies. In regard to previous
clinical findings in WS (very rare reports of anosmia and
hypogonadism and/or cryptorchidism among almost 100(C) Higher magnification of the regions boxed in (B) shows the presence of OECs enshea
heterozygous Sox10 mutant embryos and the absence of these cells in the homozygous em
(D and E) Higher magnification of the nasal mesenchyme (D) or ONL (E) immunostained fo
b-galactosidase (green), and the neuronal marker (TUJ1; blue), as indicated in the figure
homozygous (right panels) mutant embryos.
Abbreviations are as follows: OB, olfactory bulb; and OE, olfactory epithelium.
The American Journal of Humareported persons with different
SOX10 mutations) and the recent
observation that 88% of WS individ-
uals with a SOX10 mutation and in-
ner-ear morphological abnormalities
also have olfactory-bulb agenesis, it
remains possible that anosmia andhypogonadism have been underestimated in WS. This
phenomenon could possibly be explained in part because
people usually do not spontaneously complain of anosmia
and by the fact that WS is often diagnosed in childhood.
The involvement of SOX10 in mouse olfactory develop-
ment was not suspected until recently, when its expression
was reported in OECs.29–31 Here, we show that SOX10thing the vomeronasal nerve fibers in the
bryos.
r an OEC marker (BLBP, P75, or S100; red),
, in Sox10 heterozygous (left panels) and
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Figure 7. Summary of the Defects
Observed in the Sox10 Mutant Embryo
(A) Schematization of the cut planes (a and
b) drawn in (B) on the head of an E14.5
mouse embryo.
(B) Summary of the defects observed in the
Sox10 homozygous mutant embryos
(Sox10lacZ/lacZ, right panel) compared to
wild-type embryos (left panel). The OECs
are shown in green, the nerve fibers are
in blue, and the GnRH-synthesizing cells
are in red. Abbreviations are as follows:
OE, olfactory epithelium; OB, olfactory
bulb; POA, preoptic area; and VNO, vom-
eronasal organ.plays a major role in the development of these peculiar
NC-derived glial cells. In Sox10-null mutant embryos, a
large part of the peripheral embryonic olfactory system
lacked OECs at the embryonic stages analyzed.
Our results show that the OEC deficiency occurs prior
to E12.5 in mice. On the basis of current knowledge
about SOX10 function in other tissues, the defect most
likely occurs between the emergence of NC cells from the
neural tube and their arrival at the olfactory placode.
SOX10 is thought to play a role in sustaining the survival
of multipotent NC cells. In the absence of SOX10, a dra-
matic increase in cell death has been reported for vagal
NC cells prior to their entry into the foregut, as well as in
various other NC cell derivatives.43–47
The remaining OECs were located in the uppermost part
of the frontonasal mesenchyme, the migratory mass, and
the ONL. They had an abnormal expression profile and
formed a discontinued and disorganized layer around the
olfactory bulbs, indicating that SOX10 is also probably
involved in their identity and function at several locations.
Several explanations can be proposed as to why some
OECs persisted in the mutant mice. One possibility is
that not all OECs are dependent on SOX10. Another
hypothesis is a partial functional redundancy between
SOX10 and another protein of the SOX family. SOX8,
which together with SOX10 and SOX9 forms the E sub-
group of SOX transcription factors, is a good candidate
given its expression in the ONL during embryogenesis
and the described redundancy between SOXE subfamily
members in other tissues.48–50720 The American Journal of Human Genetics 92, 707–724, May 2, 2013Despite the markedly reduced
number of OECs, the olfactory, vom-
eronasal, and terminal nerves had
formed in the Sox10-null embryos,
as had the olfactory bulbs. Given
that OECs not only ensheathe and
fasciculate the nerve fibers but also
extend processes ahead of the pioneer
olfactory axons they ensheathe, sug-
gesting that they orchestrate their
growth and guidance,32,51 this
finding might be surprising. How-ever, although the olfactory axons were formed and
extended some processes toward the migratory mass and
the olfactory bulb in the Sox10-null mutant embryos, we
found that they were partially misrouted and defascicu-
lated, thus confirming the role of OECs in these processes.
In mice, neuroendocrine GnRH cells begin to leave the
epithelium of the olfactory pit at approximately E11.5.
They migrate in close association with growing fibers of
the vomeronasal and terminal nerves and then penetrate
into the rostral forebrain and continue their migration
toward the hypothalamus along the terminal nerve or a
branch of the vomeronasal nerve.52 In E14.5 Sox10-null
embryos, the latest embryonic stage we could examine,
GnRH cells accumulated outside the brain, along the
vomeronasal and terminal nerve pathways, in the regions
devoid of OECs. Few GnRH cells were seen in the forebrain
of these mice, which could reflect an impaired or delayed
migration. To the extent that mice and humans are
comparable, it remains to be determined whether the
defective GnRH cell migration in this particular genetic
form of KS is primarily due to the absence of OECs on
the vomeronasal and terminal nerve trajectories or to the
defective structure of these nerves, as previously suggested
in other genetic forms.12
All the abnormalities we found in the Sox10 mutant
mice were observed in homozygous embryos, and embry-
onic lethality of these mice precludes further testing of
late olfactory development and fertility. In the normal
ONL, OECs contribute to the defasciculation, sorting,
and refasciculation of axons and are therefore crucial to
the formation of the olfactory-bulb glomeruli and to the
establishment of the olfactory topographic map.32 They
are also involved in the renewal of olfactory receptor neu-
rons and their axonal growth throughout life. Accordingly,
it is tempting to speculate that the defect in the number
and function of OECs in Sox10 mutant mice could have
drastic consequences on the maturation of the olfactory
bulbs and the ability of olfactory nerve fibers to renew
throughout life. The use of a conditional knockout mouse
model to avoid lethality would be of interest to explore
the late consequences of the absence of SOX10 in the
peripheral olfactory system.
SOX10 mutations have been found in the heterozygous
state in both KS and WS individuals. No reproduction
defect has been reported in Sox10 heterozygous mutant
mice, suggesting that both olfaction and GnRH neuro-
secretion are not strongly affected, although it remains
possible that subtle, still unrecognized defects in OECs
have some functional consequences in adult mice. By
contrast, depigmentation and megacolon are found in
heterozygous mice as they are in WS4 individuals. Such
differences in sensitivity to genetic diseases between mice
and humans are not rare. Alternatively, oligogenicity has
been described in KS, and mutations in unknown genes
might contribute to the disease in some instances. Notably,
the inner-ear morphological defects associated with SOX10
mutations are also quite marked and have a high pene-
trance in humans, whereas they are much less evident in
the Sox10 homozygous mutant mice.10,53
Sox10 is expressed in the melanocytic intermediate cells
of the cochlear stria vascularis; these cells produce the
endocochlear electric potential essential to the hearing
process.54 It is also widely expressed during early inner-
ear development before being restricted to the cochlear
and vestibular ganglia and to supporting cells of the sen-
sory epithelium. In addition to having a specific role in
glial development of the ganglia, SOX10 has been shown
to promote the survival of cochlear progenitors during
otocyst formation and differentiation of the organ of
Corti.53–55 In the Sox10 homozygous mutant mice, the
structure and cellular organization of the organ of Corti
appear normal but the cochlear duct is shortened and
there is no apparent malformation of the vestibule.53 In
humans, apart from the cochlear degeneration thought
to take place in WS in the absence of intermediate cells
of the stria vascularis, a proportion of WS individuals
with SOX10mutations had an enlarged vestibule, agenesis
or hypoplasia of semicircular canals, and an abnormally
shaped cochlea.10 Together, these results suggest that the
high penetrance of deafness among persons who carry
SOX10mutations is most likely the consequence of several
different defects in the development of the inner ear.
MRI or CT scans of the temporal bone have been
performed in four of the seven individuals. Abnormal
images were not found in case B (not all the temporal
bone structures could be analyzed, but the semicircular
canals were present and normally shaped). A vestibuloco-The Amchlear dysplasia was reported in case D. The temporal
bone CT scan of case C showed a bilateral hypoplasia of
the lateral and posterior semicircular canals, as well as
a vesicular vestibule on one side and an enlargement of
the vestibular aqueduct on the other side. The CT scan of
case E showed bilateral enlargement of the vestibule and
hypoplasia of the lateral semicircular canals. Interestingly,
the association between semicircular canal hypoplasia or
agenesis and olfactory-bulb agenesis and hypogonado-
tropic hypogonadism is also found in CHARGE (coloboma,
heart defects, choanal atresia, retardation, genital and ear
anomalies) syndrome, due to mutations in CHD7.56 It is
not difficult to distinguish individuals affected by typical
CHARGE syndrome from persons carrying SOX10 muta-
tions, but in individuals who are affected by mild forms
of CHARGE syndrome and who thus do not show all the
cardinal signs of the disease, it might be difficult to differ-
entiate this condition in the absence of a complete clinical
description.56–58 From now on, the existence of semicir-
cular canal hypoplasia or agenesis in a person affected by
KS should be considered an indication for both CHD7
and SOX10 molecular analyses. Isolated or minor signs of
CHARGE syndrome, such as coloboma and heart defects
but also facial asymmetry, malformations of the middle
or external ear, and a hypoplastic vestibule, might point
toward a CHD7 mutation, whereas some depigmentation
features or an enlarged vestibule might point to a SOX10
defect.
Our findings implicate NC-derived OECs in the patho-
genesis of KS, thus defining the SOX10-related genetic
form of the disease as a neurocristopathy. The peripheral
olfactory nervous system is unique in that it renews
throughout life, a property attributed to the presence of
the OECs, which makes them strong candidates for cell-
mediated repair of a variety of neural lesions.32,51 Despite
this major medical relevance, the consequences of the
absence or depletion of OECs in the peripheral olfactory
system have been poorly characterized. In this respect, the
Sox10-knockoutmousemight prove to be a valuablemodel.
In summary, we characterized an additional role for
SOX10 in human pathology 15 years after the cloning
and first implication of this gene in WS. We found
SOX10 loss-of-function mutations in individuals demon-
strating the clinical association between KS and hearing
impairment and more rarely in individuals affected by KS
without associated features. From now on, SOX10 should
be the first gene to be tested for the presence of
mutations in the association between KS and hearing
impairment. On the basis of a mouse-model study, we sug-
gest that this particular genetic form of KS results from a
primary defect affecting OECs during early embryonic
development of the peripheral olfactory system.Supplemental Data
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